Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer

This study has been completed.
Information provided by (Responsible Party):
Samsung Medical Center Identifier:
First received: January 7, 2010
Last updated: April 8, 2013
Last verified: January 2012

January 7, 2010
April 8, 2013
November 2008
April 2012   (Final data collection date for primary outcome measure)
time to progression [ Time Frame: every 6 weeks ]
Same as current
Complete list of historical versions of study NCT01238055 on Archive Site
  • Response rate [ Time Frame: 12 months ]
  • Overall survival [ Time Frame: 12 months ]
  • Progression free survival [ Time Frame: 12 months ]
Same as current
Not Provided
Not Provided
Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer
Randomized Phase II Trial of Sunitinib and Docetaxel in Advanced Gastric Cancer Patients Who Had Prior Chemotherapy With Fluoropyrimidine and Platinum
The purpose of this study is to determine whether Sunitinib and Docetaxel is effective in the treatment of advanced gastric cancer patients who had prior chemotherapy with fluoropyrimidine and platinum.
This is a randomized phase II trial of Sunitinib and Docetaxel in advanced gastric cancer patients who had prior chemotherapy with Fluoropyrimidine and Platinum.
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Advanced Gastric Cancer
  • Drug: Docetaxel + Sunitinib

    Docetaxel 60 mg/m2 iv, every 3 weeks

    Sunitinib 37.5 mg qd daily, every 3 weeks

  • Drug: Docetaxel only
    Docetaxel 60 mg/m2 iv
  • Experimental: Docetaxel + Sunitinib
    Docetaxel and Sunitinib
    Intervention: Drug: Docetaxel + Sunitinib
  • Active Comparator: Docetaxel
    Docetaxel only
    Intervention: Drug: Docetaxel only
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
October 2012
April 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. histologically or cytologically confirmed diagnosis of gastric adenocarcinoma or gastroesophageal junction adenoca (i.e. an adenocarcinoma with > 50% extension in the stomach)
  2. patients must present with stage IV disease not amenable to surgery, radiation or combined modality therapy with curative intent. Patients previously undergoing local treatment (surgery and/or radiation) must have subsequently progressed or recurred
  3. prior chemotherapy wit fluoropyrimidine and platinum
  4. measurable or evaluable disease according to RECIST
  5. age, 18 years or older
  6. ECOG performance status 0 - 2
  7. adequate organ function as defined by the following criteria absolute neutrophil count (ANC) ≥ 1,500/ul platelets ≥ 100,000/ul AST/ALT ≤ 2.5 x ULN, ≤ 5.0 x ULN if liver involvement Total serum bilirubin ≤ 2.0 mg/dL
  8. life expectancy of ≥ 3 months
  9. signed written informed consent

Exclusion Criteria:

  1. more than one prior chemotherapy for metastatic disease
  2. severe co-morbid illness and/or active infections
  3. NCI CTCAE Grade 3 hemorrhage from any cause < 4 weeks before enrollment
  4. preexisting uncontrolled hypertension as documented by 2 baseline blood pressure readings taken at least 1 hour apart
  5. pregnant or lactating women
  6. active CNS metastases not controllable with radiotherapy or corticosteroids
  7. active and uncontrollable bleeding from gastrointestinal tract
  8. known history of hypersensitivity to study drugs
  9. prior treatment with sunitinib
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
Not Provided
Not Provided
Not Provided
Samsung Medical Center
Samsung Medical Center
Not Provided
Principal Investigator: Jeeyun Lee, M.D., Ph.D. Samsung Medical Center, Seoul, Korea
Samsung Medical Center
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP